HCV Advocate Logo
Contact Us Site Map  
For living Positivley. Being Well
About Hepatitis
News Updates
News Review
Conference Reports
News Articles
HCV Advocate Newsletter
Sign up for Email Updates
Community & Support
Resource Library
About Hcsp
 
 
Conference Reports

Back to Conference Reports

Abstract Reports on HBV from the American Association for the Study of Liver Disease

  1. DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN CHRONIC TYPE B LIVER DISEASES: A STUDY ON INFLUENCE OF FIBROSIS, INFLAMMATION AND HBV GENOTYPES—abstract 806
    Hajime Sumi, Fumio Imazeki, Osamu Yokosuka, Tomoko Kurihara, Takaaki Imamura, Tatsuo Kanda, Keni chi Fukai, Hiromitsu Saisho, Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan
  2. RESIDUAL HEPATITIS B INFECTION—Abstract 822
    Karen Doucette, Manna Zhang, Kim Hawkins, Kelly D Kaita, Gerald Y Minuk, University of Manitoba, Winnipeg, MB, Canada
  3. EARLY LAMIVUDINE THERAPY MAY PREVENT LIVER FAILURE IN PATIENTS WITH FULMINANT HEPATITIS B—Abstract 848
    Hans L Tillmann, Heiner Wedemeyer, Johannes Hadem, Thomas Rudolph, Anasthasia Dick, Ingolf Schedel, Andrea Schneider, Christian Trautwein, Michael P Mantis, Dept. of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
  4. THERAPEUTIC EFFICIENCY OF DNA VACCINE IN ASSOCIATION WITH LAMIVUDINE FOR CHRONIC HEPATITIS B TREATMENT—abstract 834
    Alex- andre Thermet, Nathalie Cagnon, Nelly Courant, INSERM U271, Lyon, France; John Rhodes, GlaxoWellcome, Stevenage, UK; Christian Trepo, Fa bien Zoulim, Lucyna Cova, INSERM U271, Lyon, France
  5. ADEFOVIR DIPIVOXIL (ADV) 10 MG FOR THE TREATMENT OF PATIENTS WITH HBEAG+ CHRONIC HEPATITIS B: CONTINUED EFFI CACY BEYOND 48 WEEKS—abstract 840
    Patrick Marcellin, Hopital Beaujon, Clichy, France; Ting-Tsung Chang, National Cheng Kung University, Tainan, Taiwan; Seng-Gee Lim, National University Hospital, Singapore, Singapore; William Sievert, Monash Medical Centre, Clayton, Australia; Myron Tong, Huntington Memorial Hospital Liver Center, Pasadena, CA; AnantJain, CraigJames, Shan Shan Chen, John Fry, Carol Brosgart, Gilead Sciences, Inc., Foster City, CA
  6. AST/ALT IN COMBINATION WITH PLATELET COUNTS AS PREDICTORS OF FIBROSIS STAGE IN CHRONIC HEPATITIS B—abstract 828
    Soo-Young Park, Chang-Min Cho, Won-Young Tak, Young-Oh Kweon, Sung-Kook Kim, Yong Whan Choi, Kyungpook National University, School of Medicine, Daegu, South Korea
  7. ADEFOVIR DIPIVOXIL (ADV) FOR THE TREATMENT OF CHRONIC HEPATITIS B IN PATIENTS PRE-AND POST-LIVER TRANSPLANTION (OLT) WITH LAMIVUDINE-RESISTANT (LAM-R) HEPATITIS B VIRUS (HBV) PATIENTS—abstract 831
    Eugene Schiff, Center for Liver Diseases, University of Miami, Miami, FL; Ching-Lung Lai, Queen Mary Hospital, Hong Kong, China; Peter Neuhaus, Charite Campus Virchow, Berlin, Germany; Hans Tillmann, Hannover Medical School, Hannover, Germany; Didier Samuel, Paul Brousse Hospital, Villejuif, France; Jean-Pierre Villeneuve, CHUM-Campus Saint-Luc, Montréal, PQ, Canada; Stefanos Hadziyannis, Henry Dunant Hospital, Athens, Greece; Shelly Xiong, Nicole Lama, Craig James, John Fry, Hamid Namini, Sally Van Doren, Carol Brosgart, Gilead Sciences, Inc., Foster City, CA
  8. ANTIVIRAL ACTIVITY, SAFETY, AND INCIDENCE OF RESISTANCE HBV IN CHRONICALLY INFECTED HEPATITIS B PATIENTS (CHB) GIVEN ONCE DAILY EMTRICITABINE FOR 2 YEARS—abstract 838
    Robert Gish, CA Pacific Medical Ctr, San Francisco, CA; Nancy Leung, Prince of Wales Hospant Chinese Univ of Hong Kong, Shatin, Hong Kong; Chia Wang, Lawrence Corey, Univ of Washington, Seattle, WA; Stephen Sacks, Viridae Clinical Sciences Inc., Vancouver, BC, Canada; Michael Fried, Univ of North Carolina, Chapel Hill, NC; Teresa Wright, Veterans Medical Center San Francisco, San Francisco, CA; Trinh Huy, CA Pacific Medical Ctr, San Francisco, CA; Francis Chan, Prince of Wales Hosp and Chinese Univ of Hong Kong, Shatin, Hong Kong; Franck Rousseau, Triangle Pharmaceuticals, Durham, NC; Herve Mommeja-Marin, Triangle Pharmaceuticals, lnc, Durham, NC; Andrea Snow, Jane Anderson, Triangle Pharmaceuticals, Inc., Durham, NC; Amy Rigney, Triangle Pharmaceuticals, Chapel Hill, NC; Elsa Mondou, Triangle Pharmaceuticals inc., Durham, NC
  9. HEPDIRECTTM PRODRUGS: A NOVEL STRATEGY FOR TARGETING DRUGS TO THE LIVER—abstract 551
    Mark D Erion, Timothy J Colby, K Raja Reddy, Deidre A MacKenna, Serge H Boyer, James M Fujitaki, David L Linemeyer, David A Bullough, Paul D van Poelje, Metabasis Therapeutics, Inc., San Diego, CA
  10. HBV Genotype B is Associated with a Higher Response Rate to Interferon Therapy than Genotype C—abstract 552
    Chun Tao Wai, Chi-Jen Chu, Munira Hussain, Anna S Lok, University of Michigan Medical Center, Ann Arbor, MI
  11. POTENT ANTI-HBV ACTIVITY OF ACH-126,443 CORRELATED WITH 14-DAY PHARMACOKINETICS AND SAFETY: PREDICTIONS FOR ACTIVITY AGAINST YMDD MUTANT STRAINS—abstract 837
    Nezam H Afdhal, Beth Israel Deaconess Hospital, Boston, MA; Christopher B O'Brien, University of Miami, Miami, FL; Scott C Oshana, Lisa M Dunkle, Achillion Pharmaceuticals, Inc, New Haven, CT
  12. Distribution of HBV Genotypes and Serum HBV DNA Response in 694 Patients in Phase 3 Studies of Adefovir Dipivoxil – abstract 839
    Christopher Westland, William E Delaney IV, Huiling Yang, Shan-Shan Chen, Gilead Sciences, Foster City, CA; Robert Gish, California Pacific Medical Center, San Francisco, CA; Patrick Marcellin, Hopital Beaujon, Clichy, France; John Fry, Carol Brosgart, Craig Gibbs, Michael Miller, Shelly Xiong, Gilead Sciences, Foster City, CA
  13. Rising Burden of Hepatitis B in the Untied States: Should ‘The Other’ Virus Be Forgotten? – Abstract 223
    W Ray Kim, Michael B Ishitani, E Rolland Dickson, Mayo Clinic and Foundation, Rochester, MN
  14. Clinical Research on the Treatment of Chronic Hepatitis B with Thymosin-A1 and Lamivudine Versus Interferon and Lamivudine – abstract 1843
    Thuy T Pham Thi, Medical Medic Center, Ho Ch Minh City, Vietnam
  15. Biochemical, Serological, Virological and Histological Outcomes of Lamivudine Therapy in Hepatitis B Renal Transplant Patients—abstract 1844
    David J Machado, Hospital das Clinicas-Univer sity of Sao Paulo, Sao Paulo, Brazil; Joao R Pinho, Marcilio F Lemos, Regina C Moreira, Adriana P Campri, Alessandra E Nascimento, Institute Adolfo Lutz-Virology Department, Sao Paulo, Brazil; Alvaro P Filho, Hospital Sao Paulo-Federal University of Sao Paulo, Sao Paulo, Brazil; Venancio A Ferreira, Flair Carilho, Luiz Estevan Ianhez, Hospital das Clinicas-University of Sao Paulo, Sao Paulo, Brazil
  16. Pegylated Interferon Has Additional Antiviral Effect on Lamivudine in the Treatment of Chronic Hepatitis B – abstract 1846
    Henry L Chan, May L Wong, Nancy W Leung, Alex Y Hui, Lawrence C Flung, Francis K Chan, Joseph J Sung, The Chinese University of Hong Kong, Shatin, Hong Kong
  17. Co-Infection with HIV and HBV: The Effect of Tenofovir Disoproxil Fumarate in Lamivudine and Famciclovir Experienced Patients --- abstract 1911
    James Park, New York University School of Medicine, New York, NY; James Braun, Astor Medical; St Vincent’s Hospital, New York, NY; Stacy Kreiswirth, Astor Medical, New York, NY; Debbie Goldman, Mount Sinai School of Medicine, New York, NY; Michael Mullen, Cabrini Medical Center, New York, NY; Douglas Dieterich, Mount Sinai School of Medicine, New York, NY
  18. Treatment of HBEAG-Negative Chronic Hepatitis B with Sequential Lamivudine and Interferon of 12-Month Duration and a 6-Month Overlap: Preliminary Results –abstract 1912
    Emanuel K Manesis, George V Papatheodoridis, Alexandra Alexopoulou, Hippokration General Hospital, Athens, Greece
  19. HBV Drug Resistance Mutants Patterns During Lamivudine Therapy in Patients with Chronic Hepatitis – abstract 1914
    Maria Buti, Auristela Valdes, Francisco Rodriguez-Frias, Rosendo Jardi, Alejandro Al lapuz, Rafael Esteban Mur,Jaime Guardia, Hospital Universitari Vail d’Hebron, Barcelona, Spain
  20. Factors Related to Post-Treatment Relapse in Chronic Hepatitis B Patients who Lost HBeAg After Lamivudine Therapy—abstract 1907
    Kwan Soo Byun,Jong En Yeon, Chang Hong Lee, Korea University College of Medicine, Seoul, South Korea; Oh Sang Kwon, Ju Hyun Kim, Ga chon University College of Medicine, Inchon, South Korea
  21. Prevalence and Characterization of Lamivudine Resistant HBV Mutations in HIV and HBV Co-Infected Individuals—abstract 1909
    Louise Cooley, Victorian Infectious Diseases Reference Laboratory and The Alfred Hospital, Melbourne, Australia; Anna Ayres, Angeline Batholomeusz, Victorian Infectious Diseases Reference Laboratory, Mel bourne, Australia; Sharon Lewin, Victorian Infectious Diseases Service,Parkville, Australia; Suzanne Crowe, The Burnet Centre, Fairfield, Australia;Anne Mijch, Stuart Roberts, The Alfred Hospital, Prahran, Australia; Stephen A Locarnini, Victorian Infectious Diseases Reference Laboratory, Melbourne,Australia; Joseph Sasadeusz, The Alfred Hospital, Prahran, Australia
  22. Efficacy of Lamivudine In Patients with Cirrhosis Due to Hepatitis B – abstract 1923
    David Moskovitz, University Health Network-Toronto Western Hospital, University of Toronto, Toronto, ON, Canada; Carla Osiowy, Population and Public Health, Health Canada, Winnipeg, MB, Canada; Jenny Heathcote, University Health Network-Toronto Western Hospital, University of Toronto, Toronto, ON, Canada


Back to Conference Reports


About Hepatitis | News Updates | Community & Support | Resource Library | About HCSP | Contact Us | Site Map | Home

Hepatitis C Support Project

(C) 2003. Hepatitis C Support Project

Medical  Writers' Circle
Fact Sheets